• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Weis Holger

    6/4/26 8:47:04 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JUNS alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Weis Holger

    (Last)(First)(Middle)
    C/O JUPITER NEUROSCIENCES, INC.
    1001 NORTH US HYWAY 1, SUITE 504

    (Street)
    JUPITER FLORIDA 33477

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    JUPITER NEUROSCIENCES, INC. [ JUNS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    06/02/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Stock Option$0.278306/02/2026A100,000 (1)06/02/2036Common Stock100,000$0100,000D
    Explanation of Responses:
    1. The options were granted under the Issuer's 2025 Equity Incentive Plan. The options vest over three years commencing from September 2, 2026 in equal quarterly installments subject to continued service through each vesting date.
    /s/ Holger Weis06/04/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $JUNS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JUNS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $JUNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Brady Allison W

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    6/5/26 8:23:57 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Scientific Officer Hayward Marshall A.

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    6/4/26 9:00:06 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Elmasri Saleem

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    6/4/26 9:01:20 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JUNS
    SEC Filings

    View All

    SEC Form 424B3 filed by Jupiter Neurosciences Inc.

    424B3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

    5/21/26 12:39:12 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Jupiter Neurosciences Inc.

    424B3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

    5/21/26 9:54:45 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jupiter Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

    5/21/26 9:51:20 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JUNS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease

    Investigational Oral Candidate JOTROL™ Addresses a Parkinson's Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage biopharmaceutical company developing investigational therapies for neurodegenerative diseases, today announced that patient enrollment is now underway in its Phase 2a RESET clinical trial (NCT07592767) for JOTROL™ (investigational trans-resveratrol micellar formulation) in Parkinson's Disease (PD), with first patient dosing expected in the near term. Parkinson's Disease affects an estimated 1.1 million people in the United States, with roughly 90,000 new

    5/27/26 7:30:00 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

    Cash Runway Extended to Finance the Parkinson's Program; Debt Paydown Improves Shareholder Equity Position  Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced the closing of its registered direct offering, pursuant to the securities purchase agreements with certain investors, for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering were approximately $2.0 million (the "Offering"). "Yesterday's capital raise helps the Company p

    5/21/26 5:15:00 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

    Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering"). D. Boral Capital LLC is acting as the exclusive placement agent for the Offering. The closing of the Offering is expected to occur on or about May 21, 2026, subject to the satisfaction of customary closing conditions. T

    5/20/26 2:38:00 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JUNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres + Chief Business Officer Silva Alison D. bought $772 worth of shares (750 units at $1.03), increasing direct ownership by 0.67% to 112,777 units (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/3/25 8:56:52 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman Rosen Christer bought $3,667 worth of shares (3,600 units at $1.02), increasing direct ownership by 0.03% to 11,078,892 units (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/3/25 2:53:00 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pres + Chief Business Officer Silva Alison D. converted options into 110,227 shares and bought $1,855 worth of shares (1,800 units at $1.03) (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/1/25 7:55:51 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JUNS
    Leadership Updates

    Live Leadership Updates

    View All

    Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board

    New Advisors Bring Nationwide Pharmacy and Wellness Distribution Expertise to Nugevia™ Consumer Longevity Line Compounding Pharmacy and Wellness Channels Represent Over $1.5 Billion Addressable Market for Practitioner-Grade Nutraceuticals in the U.S. JUPITER, FL, April 07, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced the appointment of Kristopher Fishman and Sanjiv Lal to the Nugevia™ Advisory Board. The two bring direct distribution relationships across compounding pharmacies and wellness channels, an addressable market th

    4/7/26 8:00:00 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care